Non-hodgkin Lymphoma,B Cell Clinical Trials

31 clinical trials for Non-hodgkin Lymphoma,B Cell across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• CAR T-cell Therapy in Patients With Renal Dysfunction — RECRUITING · PHASE2
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice — RECRUITING
• SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project — RECRUITING
• Universal CAR-T Cell Therapy for NHL — RECRUITING · NA
• The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) — RECRUITING · PHASE2
• A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) — RECRUITING · PHASE1
• Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). — RECRUITING · PHASE1
• Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL — RECRUITING · PHASE1
• Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research — RECRUITING · PHASE1
• CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL — RECRUITING · PHASE1
• Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL — RECRUITING · PHASE1
• B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 — RECRUITING · PHASE4
• A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL — RECRUITING · PHASE1
• Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma — TERMINATED · NA
• LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · NA
• A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders — COMPLETED · PHASE1
• An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders — NOT_YET_RECRUITING
• A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma — NOT_YET_RECRUITING · PHASE1
• The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) — OTHER · NA
• TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL — OTHER · PHASE1
• Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — COMPLETED · PHASE2
• PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma — TERMINATED · PHASE2
• Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma — OTHER · PHASE1
• Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma — OTHER · PHASE1
• T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies — OTHER · PHASE1
• Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas — OTHER
• Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy — OTHER · PHASE1
• Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 — OTHER · PHASE1
• CART-19 Immunotherapy in Mantle Cell Lymphoma — OTHER · PHASE1

Refine this search